逍遥散治疗乳腺增生病临床疗效的系统评价

Systematic Review of Xiaoyao Powder on Clinical Effect for Treatment on Mammary Gland Hyperplasia

目的:系统评价逍遥散(丸)治疗乳腺增生病的有效性。方法:检索中国生物医学文献数据库、中国知网、维普数据库和万方数字化期刊群等数据库,搜集逍遥散(丸)治疗乳腺增生的随机对照试验,进行资料提取和质量评价,运用RevMan 5.3软件进行数据分析,并采用GRADE系统对证据质量和等级推荐进行分级。结果:共纳入11项研究,1 644名试验者。Meta分析结果显示,逍遥散(丸)与常规西药治疗相比有一定的疗效优势(OR=4.30,95%CI[2.83,6.52])。基于GRADE系统,总有效率结局指标的证据质量为"极低质量",推荐等级为弱推荐。结论:逍遥散(丸)治疗乳腺增生病是一种有效的疗法,但由于纳入研究质量偏低,今后仍需要高质量的随机对照临床试验加以验证。

Objective：To review the effectiveness of xiaoyao powder （bolus） on treatment for mammary gland hyperplasia. Methods：Database such as Chinese Biomedical Literature Database,China Knowledge Network,Vip Database and Wanfang Digital Journal Group were retrieved to search the randomized controlled trials for treatment of xiaoyao powder （bolus） on mammary gland hyperplasia for data extraction and quality evaluation. The data were analyzed with RevMan 5.3 software and GRADE system was applied to classify the evidence quality and grade recommendation. Results ： 11 trials were identified, covering 1 644 patients. Meta-analysis results showed that xiaoyao powder （bolus） had a competitive edge on curative effect in comparison with conventional western medicine （OR=4.30,95%CI [2.83,6.52]）. Based on the GRADE system,the evidence quality of the total effective outcome was ＂very low quality＂ with weak recommendation level presented. Conclusions：The treatment of xiaoyao powder （bolus） on mammary gland hyperplasia is an effective therapy. But high-quality randomized controlled clinical trials were needed to be verified due to the low quality of inclusion studies.